Skip Nav Destination
Issues
15 February 2011
-
Cover Image
Cover Image
The reassessment of prostate cancer surgical specimens led to reclassification of standard prognostic variables in 15% of cases, including modification of the pathological stage. The radical prostatectomy from this patient with biochemical relapse after surgery was initially classified as pt2, but showed after review a focal extraprostatic extension, with a tumor focus adjacent to periprostatic adipose tissue, beyond the rounded boundary of the gland. For further details, please see Fromont and co-workers on page 836 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Statistics in CCR
Molecular Pathways
Review
Human Cancer Biology
Natural Killer Cells are Scarce in Colorectal Carcinoma Tissue Despite High Levels of Chemokines and Cytokines
Niels Halama; Monika Braun; Christoph Kahlert; Anna Spille; Christian Quack; Nuh Rahbari; Moritz Koch; Jürgen Weitz; Matthias Kloor; Inka Zoernig; Peter Schirmacher; Karsten Brand; Niels Grabe; Christine S. Falk
Cancer Therapy: Preclinical
Silibinin Prevents Lung Tumorigenesis in Wild-Type but not in iNOS−/− Mice: Potential of Real-Time Micro-CT in Lung Cancer Chemoprevention Studies
Kumaraguruparan Ramasamy; Lori D. Dwyer-Nield; Natalie J. Serkova; Kendra M. Hasebroock; Alpna Tyagi; Komal Raina; Rana P. Singh; Alvin M. Malkinson; Rajesh Agarwal
Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
Ursula Kortmann; Jessica N. McAlpine; Hui Xue; Jun Guan; Gavin Ha; Sophie Tully; Sharaz Shafait; Alan Lau; Aaron N. Cranston; Mark J. O'Connor; David G. Huntsman; Yuzhuo Wang; C. Blake Gilks
Imaging, Diagnosis, Prognosis
A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma
Inge M. Ambros; Bettina Brunner; Gerhard Aigner; Clare Bedwell; Klaus Beiske; Jean Bénard; Nick Bown; Valerie Combaret; Jerome Couturier; Raffaella Defferrari; Nicole Gross; Marta Jeison; John Lunec; Barbara Marques; Tommy Martinsson; Katia Mazzocco; Rosa Noguera; Gudrun Schleiermacher; Frank Speleman; Ray Stallings; Gian Paolo Tonini; Deborah A. Tweddle; Alexander Valent; Ales Vicha; Nadine Van Roy; Eva Villamon; Andrea Ziegler; Sandra Preuner; Mario Drobics; Ruth Ladenstein; Gabriele Amann; Robert J.L. Schuit; Ulrike Pötschger; Peter F. Ambros
Serum Biomarker Panels for the Detection of Pancreatic Cancer
Randall E. Brand; Brian M. Nolen; Herbert J. Zeh; Peter J. Allen; Mohamad A. Eloubeidi; Michael Goldberg; Eric Elton; Juan P. Arnoletti; John D. Christein; Selwyn M. Vickers; Christopher J. Langmead; Douglas P. Landsittel; David C. Whitcomb; William E. Grizzle; Anna E. Lokshin
Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker
Véronique Hofman; Christelle Bonnetaud; Marius I. Ilie; Philippe Vielh; Jean Michel Vignaud; Jean François Fléjou; Sylvie Lantuejoul; Eric Piaton; Nadine Mourad; Catherine Butori; Eric Selva; Michel Poudenx; Stéphanie Sibon; Sabrina Kelhef; Nicolas Vénissac; Jean-Philippe Jais; Jérôme Mouroux; Thierry Jo Molina; Paul Hofman
Cancer Therapy: Clinical
Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents
I. Jolanda M. de Vries; Chiara Castelli; Caroline Huygens; Joannes F.M. Jacobs; Julie Stockis; Beatrice Schuler-Thurner; Gosse J. Adema; Cornelis J.A. Punt; Licia Rivoltini; Gerold Schuler; Pierre G. Coulie; Sophie Lucas
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Jennifer R. Diamond; Bruno R. Bastos; Ryan J. Hansen; Daniel L. Gustafson; S. Gail Eckhardt; Eunice L. Kwak; Shuchi S. Pandya; Graham C. Fletcher; Todd M. Pitts; Gillian N. Kulikowski; Mark Morrow; Jamie Arnott; Mark R. Bray; Carolyn Sidor; Wells Messersmith; Geoffrey I. Shapiro
Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
Richard Quek; Qian Wang; Jeffrey A. Morgan; Geoffrey I. Shapiro; James E. Butrynski; Nikhil Ramaiya; Tarsha Huftalen; Nicole Jederlinic; Judith Manola; Andrew J. Wagner; George D. Demetri; Suzanne George
Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Dana Rathkopf; Glenn Liu; Michael A. Carducci; Mario A. Eisenberger; Aseem Anand; Michael J. Morris; Susan F. Slovin; Yasutsuna Sasaki; Shunji Takahashi; Seiichiro Ozono; Nga Kit Eliza Fung; Shinta Cheng; Jinping Gan; Marco Gottardis; Mary T. Obermeier; Jyotsna Reddy; Steven Zhang; Blisse J. Vakkalagadda; Leila Alland; George Wilding; Howard I. Scher; on behalf of the Prostate Cancer Clinical Trials Consortium
Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features
Charles M. Rudin; John T. Poirier; Neil N. Senzer; Joseph Stephenson, Jr.; David Loesch; Kevin D. Burroughs; P. Seshidhar Reddy; Christine L. Hann; Paul L. Hallenbeck
Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
Amod A. Sarnaik; Bin Yu; Daohai Yu; Dawn Morelli; MacLean Hall; Dilip Bogle; Lulu Yan; Stephan Targan; Jolie Solomon; Geoff Nichol; Michael Yellin; Jeffrey S. Weber
Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
Wilfred D. Stein; James L. Gulley; Jeff Schlom; Ravi A. Madan; William Dahut; William D. Figg; Yang-min Ning; Phil M. Arlen; Doug Price; Susan E. Bates; Tito Fojo
Predictive Biomarkers and Personalized Medicine
Polymorphisms inside MicroRNAs and MicroRNA Target Sites Predict Clinical Outcomes in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy
Bo-Ying Bao; Jiunn-Bey Pao; Chun-Nung Huang; Yeong-Shiau Pu; Ta-Yuan Chang; Yu-Hsuan Lan; Te-Ling Lu; Hong-Zin Lee; Shin-Hun Juang; Lu-Min Chen; Chi-Jeng Hsieh; Shu-Pin Huang
Impact of ABCB1 Allelic Variants on QTc Interval Prolongation
Tristan M. Sissung; Erin R. Gardner; Richard L. Piekarz; Reuben Howden; Xiaohong Chen; Sukyung Woo; Ryan Franke; James A. Clark; Laura Miller-DeGraff; Seth M. Steinberg; David Venzon; David Liewehr; Steven R. Kleeberger; Susan E. Bates; Douglas K. Price; Douglas R. Rosing; Christopher Cabell; Alex Sparreboom; William D. Figg
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds